<?xml version='1.0' encoding='utf-8'?>
<document id="27530708"><sentence text="Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole."><entity charOffset="75-87" id="DDI-PubMed.27530708.s1.e0" text="posaconazole" /></sentence><sentence text="Being a substrate of the cytochrome P450 3A4 (CYP3A4) isoenzyme, sirolimus metabolism is decreased when posaconazole is administered concomitantly"><entity charOffset="104-116" id="DDI-PubMed.27530708.s2.e0" text="posaconazole" /></sentence><sentence text=" However, because of the poor bioavailability of the oral suspension of posaconazole with which low plasma concentrations are obtained, CYP3A4 inhibition is weak and a 50-75% dose reduction of sirolimus is sufficient to avoid sirolimus overdosage"><entity charOffset="72-84" id="DDI-PubMed.27530708.s3.e0" text="posaconazole" /><entity charOffset="193-202" id="DDI-PubMed.27530708.s3.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.27530708.s3.e0" e2="DDI-PubMed.27530708.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27530708.s3.e0" e2="DDI-PubMed.27530708.s3.e1" /></sentence><sentence text=" The new tablet formulation allows reaching posaconazole concentrations 3-4 fold higher than those obtained with the oral suspension"><entity charOffset="44-56" id="DDI-PubMed.27530708.s4.e0" text="posaconazole" /></sentence><sentence text=" Based on a case of sirolimus overdosage following posaconazole tablets administration, we modelled the inhibition of sirolimus clearance by posaconazole, and then simulated several dosage regimens of sirolimus taken together with posaconazole tablets"><entity charOffset="20-29" id="DDI-PubMed.27530708.s5.e0" text="sirolimus" /><entity charOffset="51-63" id="DDI-PubMed.27530708.s5.e1" text="posaconazole" /><entity charOffset="118-127" id="DDI-PubMed.27530708.s5.e2" text="sirolimus" /><entity charOffset="141-153" id="DDI-PubMed.27530708.s5.e3" text="posaconazole" /><entity charOffset="201-210" id="DDI-PubMed.27530708.s5.e4" text="sirolimus" /><entity charOffset="231-243" id="DDI-PubMed.27530708.s5.e5" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e0" e2="DDI-PubMed.27530708.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e1" e2="DDI-PubMed.27530708.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e1" e2="DDI-PubMed.27530708.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e1" e2="DDI-PubMed.27530708.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e1" e2="DDI-PubMed.27530708.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e1" e2="DDI-PubMed.27530708.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e2" e2="DDI-PubMed.27530708.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e2" e2="DDI-PubMed.27530708.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e2" e2="DDI-PubMed.27530708.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e2" e2="DDI-PubMed.27530708.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e3" e2="DDI-PubMed.27530708.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e3" e2="DDI-PubMed.27530708.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e3" e2="DDI-PubMed.27530708.s5.e5" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e4" e2="DDI-PubMed.27530708.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27530708.s5.e4" e2="DDI-PubMed.27530708.s5.e5" /></sentence><sentence text=" We were able to describe well the interaction, and found a value of IC50 of posaconazole towards sirolimus clearance of 0"><entity charOffset="77-89" id="DDI-PubMed.27530708.s6.e0" text="posaconazole" /><entity charOffset="98-107" id="DDI-PubMed.27530708.s6.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.27530708.s6.e0" e2="DDI-PubMed.27530708.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27530708.s6.e0" e2="DDI-PubMed.27530708.s6.e1" /></sentence><sentence text="68 μg/mL" /><sentence text=" The simulations showed that even a 80% decrease of the daily dose of sirolimus is unsuitable in many cases with trough concentrations of posaconazole of 2 μg/mL"><entity charOffset="70-79" id="DDI-PubMed.27530708.s8.e0" text="sirolimus" /><entity charOffset="138-150" id="DDI-PubMed.27530708.s8.e1" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.27530708.s8.e0" e2="DDI-PubMed.27530708.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27530708.s8.e0" e2="DDI-PubMed.27530708.s8.e1" /></sentence><sentence text=" A decrease of 40% of the dose with spacing administrations of 3 days may be considered" /><sentence text=" The clinicians and pharmacologists must be warned that the use of posaconazole tablets may result in an inhibition of CYP3A4 of greater magnitude than with the oral suspension"><entity charOffset="67-79" id="DDI-PubMed.27530708.s10.e0" text="posaconazole" /></sentence><sentence text="" /></document>